AIMS/HYPOTHESIS: MODY is believed to be caused by at least 13 different genes. Five rare mutations at the BLK locus, including only one non-synonymous p.A71T variant, were reported to segregate with diabetes in three MODY families. The p.A71T mutation was shown to abolish the enhancing effect of BLK on insulin content and secretion from pancreatic beta cell lines. Here, we reassessed the contribution of BLK to MODY and tested the effect of BLK-p.A71T on type 2 diabetes risk and variations in related traits. METHODS: BLK was sequenced in 64 unelucidated MODY samples. The BLK-p.A71T variant was genotyped in a French type 2 diabetes case-control study including 4,901 cases and 4,280 controls, and in the DESIR (Data from an Epidemiological Study on the Insulin Resistance Syndrome) and SUVIMAX (Supplementation en Vitamines et Mineraux Antioxydants) population-based cohorts (n = 6,905). The variant effects were assessed by logistic and linear regression models. RESULTS: No rare non-synonymous BLK mutations were found in the MODY patients. The BLK p.A71T mutation was present in 52 normoglycaemic individuals, making it very unlikely that this loss-of-function mutation causes highly penetrant MODY. We found a nominal association between this variant and increased type 2 diabetes risk, with an enrichment of the mutation in the obese diabetic patients, although no significant association with BMI was identified. CONCLUSIONS/ INTERPRETATION: No mutation in BLK was found in our MODY cohort. From our findings, the BLK-p.A71T mutation may weakly influence type 2 diabetes risk in the context of obesity; however, this will require further validation.
AIMS/HYPOTHESIS: MODY is believed to be caused by at least 13 different genes. Five rare mutations at the BLK locus, including only one non-synonymous p.A71T variant, were reported to segregate with diabetes in three MODY families. The p.A71T mutation was shown to abolish the enhancing effect of BLK on insulin content and secretion from pancreatic beta cell lines. Here, we reassessed the contribution of BLK to MODY and tested the effect of BLK-p.A71T on type 2 diabetes risk and variations in related traits. METHODS: BLK was sequenced in 64 unelucidated MODY samples. The BLK-p.A71T variant was genotyped in a French type 2 diabetes case-control study including 4,901 cases and 4,280 controls, and in the DESIR (Data from an Epidemiological Study on the Insulin Resistance Syndrome) and SUVIMAX (Supplementation en Vitamines et Mineraux Antioxydants) population-based cohorts (n = 6,905). The variant effects were assessed by logistic and linear regression models. RESULTS: No rare non-synonymous BLK mutations were found in the MODY patients. The BLK p.A71T mutation was present in 52 normoglycaemic individuals, making it very unlikely that this loss-of-function mutation causes highly penetrant MODY. We found a nominal association between this variant and increased type 2 diabetes risk, with an enrichment of the mutation in the obese diabetic patients, although no significant association with BMI was identified. CONCLUSIONS/ INTERPRETATION: No mutation in BLK was found in our MODY cohort. From our findings, the BLK-p.A71T mutation may weakly influence type 2 diabetes risk in the context of obesity; however, this will require further validation.
Authors: Maciej Borowiec; Chong W Liew; Ryan Thompson; Watip Boonyasrisawat; Jiang Hu; Wojciech M Mlynarski; Ilham El Khattabi; Sung-Hoon Kim; Lorella Marselli; Stephen S Rich; Andrzej S Krolewski; Susan Bonner-Weir; Arun Sharma; Michele Sale; Josyf C Mychaleckyj; Rohit N Kulkarni; Alessandro Doria Journal: Proc Natl Acad Sci U S A Date: 2009-08-10 Impact factor: 11.205
Authors: Jacek Bochenski; Grzegorz Placha; Krzysztof Wanic; Maciej Malecki; Jacek Sieradzki; James H Warram; Andrzej S Krolewski Journal: Diabetes Date: 2006-09 Impact factor: 9.461
Authors: D Meyre; N Bouatia-Naji; V Vatin; J Veslot; C Samson; J Tichet; M Marre; B Balkau; P Froguel Journal: Diabetologia Date: 2007-08-18 Impact factor: 10.122
Authors: Stéphane Cauchi; Kevin T Nead; Hélène Choquet; Fritz Horber; Natascha Potoczna; Beverley Balkau; Michel Marre; Guillaume Charpentier; Philippe Froguel; David Meyre Journal: BMC Med Genet Date: 2008-05-22 Impact factor: 2.103
Authors: Andrea D Short; Angela Holder; Simon Rothwell; Jonathan Massey; Rachel Scholey; Lorna J Kennedy; Brian Catchpole; William Er Ollier Journal: Canine Genet Epidemiol Date: 2014-07-07
Authors: Thomas W Laver; Matthew N Wakeling; Olivia Knox; Kevin Colclough; Caroline F Wright; Sian Ellard; Andrew T Hattersley; Michael N Weedon; Kashyap A Patel Journal: Diabetes Date: 2022-05-01 Impact factor: 9.337